Close Menu


In an amended S-1, the company which filed for an IPO in July, said its net loss rose to $12.6 million, and start-up costs increased seven-fold to $4.9 million.

The Korean molecular diagnostics firm is listed on the KOSDAQ and will use funds from its IPO to further expand its footprint globally, it said.

According to an analyst note from Leerink Swann, Bruker's planned IPO for its Energy and Supercon Technologies subsidiary would allow Bruker to concentrate on its core life science business.

The company still intends to move forward with its IPO originally announced two years ago but can't say when that will happen.

The bioinformatics firm plans to list on the Ace Market of Bursa Malaysia and hopes to raise up to $5.9 million.

The company disclosed in the filing that it has generated revenue of $1.2 million — all from government grants — for the first six months of 2010. As of June 30, it had a backlog of "firm" orders of approximately $15 million, and as of mid-August, it had shipped five early-access PacBio RS instruments.

The new round brings Complete Genomics' total financing since inception to $130 million. The company closed the financing as it prepares for an initial public offering in which it aims to raise up to $86.25 million.

The firm has raised around $370 million since its inception, and is now seeking to go public in an offering that could potentially bring in $200 million.

The sequencing service company hopes to raise as much as $86.3 million from its offering.

GenMark Shares Began Trading on the Nasdaq on May 28.


A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.